Sign in / Join Now
ETFs & Funds
Great science, huge open ended opportunity.
has made it a bad stock over the past year. OVA1 ramp and PAD approval are key.
Would you buy VRML at 1.40? 2013 seems to be looking good for them. Thanks!
Add a reply...
Latest StockTalks »
people get VRML breaking news and analysis by email alert.
Get email alerts on VRML »
Get latest price
From other sites
Vermillion Announces Appointment Of Chief Medical Officer
at TheStreet (Nov 14, 2016)
Vermillion CEO To Present At Women In Bio - New York
at TheStreet (Oct 19, 2016)
ASPiRA LABs OVA1® Test Now Covered By CareFirst BlueCross BlueShield
at TheStreet (Sep 29, 2016)
Vermillion And ASPiRA LABs Applaud The FDA's Position On Ovarian Cancer Screening
at TheStreet (Sep 9, 2016)
Vermillion, Inc. Kicks Off Ovarian Cancer Awareness Month By Ringing The NASDAQ Closing Bell With Olympic Gymnast Shannon Miller, And NASCAR Driver Martin Truex, Jr.'s Life Partner, Sherry Pollex
at TheStreet (Sep 1, 2016)